Genomic Valley Biotech faces a change in ownership as new acquirers, Pankaj Grover and Abhisek Gupta, announce an open offer for 26% of the company's voting capital at Rs 30 per share. This mandatory move follows their agreement to acquire a 46.06% stake from existing promoters. Public shareholders can now prepare to participate in this exit or liquidity opportunity, pending the finalization of the tendering schedule and Letter of Offer.
Genomic Valley Biotech: Promoters Exit, New Acquirers Launch Open Offer
Offer Price: Rs 30 per share | Offer Size: 7,94,170 equity shares
Reader Takeaway: New promoters acquire 46.06% stake, triggering a mandatory open offer providing public shareholders a clear exit window.
What just happened
Fintellectual Corporate Advisors, acting as the manager to the offer, has issued a detailed public statement regarding an open offer for Genomic Valley Biotech. This follows a Share Purchase Agreement signed on October 16, 2026, wherein Mr. Pankaj Grover and Mr. Abhisek Gupta agreed to acquire 14,07,000 equity shares (46.06% voting capital) from the existing promoter group.
Why this matters
This transition marks a significant shift in management control for Genomic Valley Biotech. Under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, the acquirers are now legally obligated to provide public shareholders an opportunity to tender their holdings. The offer price is set at Rs 30 per share for up to 26% of the voting share capital.
What changes now
Public shareholders are currently in the pre-tendering phase. The acquirers have fulfilled public disclosure requirements via newspapers including Financial Express and Jansatta. The next critical steps involve the issuance of a Letter of Offer, which will outline the specific window for shareholders to tender their shares, eligibility requirements, and procedures for acceptance.
Risks to watch
Investors should be mindful that the process remains subject to ongoing SEBI regulatory reviews. Should the number of shares tendered by the public exceed the 26% offer size, proration will be applied according to regulatory norms. It is essential to review the forthcoming Letter of Offer for complete details before taking action.
What to track next
The market is awaiting the formal schedule for the tendering period. Shareholders should watch for the official announcement regarding the dates during which they can formally submit their shares for sale at the Rs 30 price point.